



Press Release

Tuesday, May 18, 2010

Strides Arcolab Limited,
Strides House,
Bannerghatta Road,
Bangalore – 560076, India

BSE: 532531
NSE: STAR

Strides Arcolab Receives ANDA approval from USFDA for Abacavir Sulfate Tablets, 300mg under PEPFAR Scheme

Total PEPFAR approvals - 14


Strides Arcolab Limited (Strides) announced today that it has received tentative approval from the United – States – Food and Drug Administration for abbreviated new drug application (ANDA) for Abacavir Sulfate Tablets, 300mg under the expedited review provisions of the President’s Emergency Plant for AIDS Relief (PEPFAR).

The company supplies ARV products to global procurement agencies and this approval adds to the overall basket of medicines available.

About Strides Arcolab Limited:

Strides Arcolab, listed on the Bombay Stock Exchange Limited (532531) and National Stock Exchange of India Limited (STAR), is a global pharmaceutical company headquartered in Bangalore, India that develops and manufactures a wide range of IP-led niche pharmaceutical products with an emphasis on sterile injectables.

The company has 14 manufacturing facilities across 6 countries with presence in more than 75 countries in developed and emerging markets. Manufacturing is ably supported by a 350-scientist strong global R&D Centre located in Bangalore. Additional information is available at the company’s website at www.stridesarco.com.



For further information, please contact:

<p>Mr. V S Iyer Executive Director Ph: +91 80 6658 0111</p> <p>Mr. N Kannan, Company Secretary (Investors) Tel : +91 80 6658 0751</p> <p>Ms. Melissa Arulappan (Media) Tel: +91 98450 22389</p>	<p>Mr. Mahesh Nair, Corporate Voice/ Weber Shandwick Mobile : +91 98803 76648 Email: maheshn@corvoshandwick.co.in</p> <p>Ms. Kasturi Wasmatar, Corporate Voice/ Weber Shandwick Mobile: 99167 28393 Email: kasturi@corvoshandwick.co.in</p>
---	---

